The epithelial-mesenchymal transition (EMT) is a complex transformation process that induces local and distant progression of many malignant tumours. Due to its complex array of proteins that are dynamically over-/underexpressed during this process, proteomic technologies gained their place in the EMT research in the last years. Proteomics has identified new molecular pathways of this process and brought important insights to develop new therapy targets. Various proteomic tools and multiple combinations were developed in this area. Out of the proteomic technology armentarium, mass spectrometry and array technologies are the most used approaches. The main characteristics of the proteomic technology used in this domain are high throughput and detection of minute concentration in small samples. We present herein, using various proteomic technologies, the identification in cancer cell lines and in tumour tissue EMT-related proteins, proteins that are involved in the activation of different cellular pathways. Proteomics has brought besides standard EMT markers (e.g., cell-cell adhesion proteins and transcription factors) other future potential markers for improving diagnosis, monitoring evolution, and developing new therapy targets. Future will increase the proteomic role in clinical investigation and validation of EMT-related biomarkers.

中文翻译：

---

蛋白质组学技术“透镜”用于肿瘤学中的上皮-间质转化过程鉴定。

上皮-间质转化（EMT）是一个复杂的转化过程，会诱导许多恶性肿瘤的局部和远距离进展。蛋白质组学技术由于其复杂的蛋白质阵列在此过程中会动态地过度/低表达，因此在最近几年的EMT研究中占有一席之地。蛋白质组学已经发现了这一过程的新分子途径，并为开发新的治疗靶点带来了重要见识。在这一领域开发了各种蛋白质组学工具和多种组合。在蛋白质组学技术中，质谱和阵列技术是最常用的方法。此领域中使用的蛋白质组学技术的主要特征是高通量和小样品中微量浓度的检测。我们在此介绍各种蛋白质组学技术，在癌细胞系和肿瘤组织中与EMT相关的蛋白质的鉴定，这些蛋白质参与不同细胞途径的激活。蛋白质组学带来了除了标准的EMT标记（例如，细胞-细胞粘附蛋白和转录因子）以外的其他潜在的潜在标记，以改善诊断，监测进化和制定新的治疗靶标。未来将增加蛋白质组学在临床研究和EMT相关生物标志物验证中的作用。并制定新的治疗目标。未来将增加蛋白质组学在临床研究和EMT相关生物标志物验证中的作用。并制定新的治疗目标。未来将增加蛋白质组学在临床研究和EMT相关生物标志物验证中的作用。